|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 微弧氧化法制备钛基HA/CS涂层及其生物学特性显示文摘采用微弧氧化法在医用钛表面制备羟基磷灰石(HA)/壳聚糖(CS)涂层。通过扫描电镜(SEM)、X射线衍射(XRD)仪、红外光谱(FTIR)仪分析涂层的形貌和物相,评价HA/CS涂层对成骨细胞的毒性及其在动物体内的生物活性,分析微弧氧化法制备钛基HA/CS涂层的特征及其在骨修复中应用的可能性。结果表明:微弧氧化法可在钛表面生成HA/CS涂层,厚度40±2 m、粗糙度3.3±0.1 m、孔隙率(30±2)%,孔隙近圆形、直径几微米到20 m,结合强度20.5±1.1 MPa;涂层中HA与CS之间没有形成化学键,晶体HA占10%,平均粒径37 nm,非晶体HA占90%;钛基HA/CS涂层材料对成骨细胞增殖具有促进作用,无细胞毒性,在动物体内能够诱导骨小梁形成,具有高的生物活性。微弧氧化法制备的高生物活性钛基HA/CS涂层材料,在骨修复方面具有良好的应用前景。 | 王国卿 Zver'kov D A 张乃生 | 2013 | 稀有金属材料与工程2013，42，12： | 6 |
| 2 | T cell prolymphocytic leukemia with new chromosome rearrangements 显示文摘 | Zver S Kokalj VN Zagradisnik B | 2004 | Acta Haematol2004，111，3： | 1 |
| 3 | Synthesis of α -SiC nanocrystals by carbothermal reduction of spherical nanoparticles of amorphous silicon dioxide显示文摘 | A. A. Zhokhov V. M. Masalov D. V. Matveev M. Yu. Maksimuk I. I. Zver’kova S. S. Khasanov S. Z. Shmurak A. P. Kiselev A. V. Bazhenov G. A. Emel’chenko | 2009 | Physics of the Solid State2009，，8： | 1 |
| 4 | Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing 显示文摘 | Cushman-Vokoun A M Stover D G Zhao Zver a1 | 2013 | Clin Colorectal Cancer2013，12，3： | 1 |
| 5 | Phase transformations in Pd40Ni40P20alloy at heating显示文摘 | Aronin A Abrosimova G Zver'kova I | 1996 | J Non-Cryst Solids1996，208，： | 1 |
| 6 | tSyclosporln A as an lmmunosuppres- sive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure显示文摘 | Zver 5 Zupan Ik' t2erneic P' | 2006 | Int J He- matol2006，83，3： | 1 |
| 7 | Theory of Photopyroelectric Spectroscopy of solids显示文摘 | Mandelis A Zver MM | | 0，，10： | 1 |
| 8 | Influence of high pressure on the formation of periodic regular structures in multi-component diffusion zones显示文摘 | Dunaev S F Zver'kov S A | | 0，，01： | 1 |
| 9 | Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure显示文摘 | Zver S Zupan IP Cernelc P | 2006 | Int J Hematol2006，83，7： | 1 |
| 10 | Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure显示文摘 | Zver S Zupan IP Cernelc P | 2006 | Int J Hematol2006，83，3： | 1 |
| 11 | Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia显示文摘 | Zver S Andoljsek D Cernelc P | 2004 | Eur J Haematol2004，72，： | 1 |
| 12 | Minimal residual disease detection in cryopreserved ovarian tissue by multicolor flow cytometry in acute myeloid leukemia 显示文摘 | Zver T Alvergnas-Vieille M Garnache-OttouF | 2014 | Haematologiea2014，99，12： | 1 |
| 13 | Immunosuppressive treatment of se- vere acute graft - versus - host disease after allo geneic hematopoi- eric stem cell transplantation 显示文摘 | Zupan IP Zver S Pretnar J | 2002 | Transplant Proc2002，34，7： | 1 |
| 14 | Immunosuppressive treatment of severe acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation显示文摘 | Zver S Pretnar J | 2002 | Transplant Proc2002，34，7： | 1 |
| 15 | Acquired haemophilia in patients with malignant disease:A case report显示文摘BACKGROUND Acquired haemophilia is a rare coagulation disorder characterized by autoantibodies against coagulation factor VIII leading to severe and potentially life-threatening haemorrhages.The underlying disorder causing the development of an autoimmune phenomenon is not always known,but 10%-15%could be linked to malignancies.Patients with cancer who require surgical resection represent a treatment challenge not solely due to increased risk of bleeding but also due to adverse events of immunosuppressive therapy.CASE SUMMARY We present the case of a 67-year-old man with non-metastatic adenocarcinoma of the distal bile duct who developed concomitant acquired haemophilia a month after having been diagnosed with malignant disease.Haemostasis was established with recombinant activated factor VII,and immunosuppressive therapy was started immediately.An extensive surgical procedure was performed in order to remove the cancer and,therefore,eliminate the inhibitory autoantibodies.Due to a complicated postoperative course,relatively short period of treatment and likelihood of micrometastases,no improvement in the patient’s status was observed.Diagnosis and treatment of acquired haemophilia as well as other coagulation disorders in patients with cancer are discussed.CONCLUSION Prompt diagnosis of acquired haemophilia is required in order to start appropriate treatment and reduce mortality.Among patients with cancer,other causes of abnormal bleeding related to malignancy should be considered. | Veronika Krašek Aleša Kotnik Hana Zavrtanik Jasna Klen Samo Zver | 2021 | World Journal of Clinical Cases2021，9，10： | 0 |
| 16 | Wells’syndrome possibly caused by hematologic malignancy,influenza vaccination or ibrutinib:A case report显示文摘BACKGROUND Wells’ syndrome(eosinophilic cellulitis) is an uncommon eosinophilic dermatosis of uncertain pathogenesis,characterized by clinical polymorphism and suggestive but nonspecific histopathologic traits.Its course is recurrent,and response to therapy is unpredictable.In a case in which the patient has a number of potential triggers for the manifestation of Wells’ syndrome skin rash,the treating physician must decide or must make an assumption in order to establish the most likely clinical scenario.This is important for the patient’s future treatment plans.CASE SUMMARY We describe the clinical case of a 46-year-old female with chronic lymphocytic leukemia who had already received treatment for several months with ibrutinib.She was diagnosed with Wells’ syndrome 10 d after an influenza vaccination containing thimerosal.Based on the literature,the patient was treated with a course of oral steroids.Resolution of clinical symptoms and rash were observed in response to the treatment.Ibrutinib was not discontinued.CONCLUSION The etiology of Wells’ syndrome remains unknown.Clinically,it resembles bacterial cellulitis.Lack of response to antibiotic treatment should lead the physician to consider a diagnosis of Wells’ syndrome.Treating the underlying condition is important and may lead to resolution of the syndrome.However,the most common and effective treatment to limit the course of the disease are systemic steroids. | Mihela Šajn Boštjan Luzar Samo Zver | 2022 | World Journal of Clinical Cases2022，10，30： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员